Crescent Biopharma (CBIO) Other Accumulated Expenses (2013 - 2024)
Crescent Biopharma (CBIO) reported Other Accumulated Expenses of $52948.0 for Q2 2024, up 156.16% year-over-year from $20670.0 in Q3 2023, and up 388.81% quarter-over-quarter from $10832.0 in Q1 2024.
Crescent Biopharma (CBIO) Other Accumulated Expenses (2013 - 2024) Analysis & Trends
Crescent Biopharma (CBIO) has 12 years of Other Accumulated Expenses data on file, last reported at $52948.0 in Q2 2024.
- Other Accumulated Expenses for Q2 2024 came in at $52948.0, up 156.16% year-over-year; the trailing twelve-month figure through Jun 2024 was $52948.0 (up 156.16% YoY), and the FY2022 annual result was $42406.0, down 53.06% from the prior year.
- Other Accumulated Expenses rose to $52948.0 in Q2 2024 per CBIO's latest filing, from $10832.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $260972.0 in Q3 2020 and troughed at $10832.0 in Q1 2024.
- A 5-year average of $106627.4 and a median of $90342.0 in 2021 frame the typical range for Other Accumulated Expenses.
- On a YoY basis, Other Accumulated Expenses climbed as much as 156.16% in 2024 and fell as far as 80.37% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $220469.0 in 2020, then slumped by 59.02% to $90342.0 in 2021, then slumped by 53.06% to $42406.0 in 2022, then plunged by 61.19% to $16457.0 in 2023, then surged by 221.74% to $52948.0 in 2024.
- Business Quant data shows CBIO's Other Accumulated Expenses at $52948.0 in Q2 2024, $10832.0 in Q1 2024, and $16457.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 52,948.00 |
| Mar 31, 2024 | 10,832.00 |
| Sep 30, 2023 | 16,457.00 |
| Jun 30, 2023 | 20,670.00 |
| Mar 31, 2023 | 55,190.00 |
| Dec 31, 2022 | 42,406.00 |
| Sep 30, 2022 | 59,336.00 |
| Jun 30, 2022 | 82,426.00 |
| Mar 31, 2022 | 109,895.00 |
| Dec 31, 2021 | 90,342.00 |
| Sep 30, 2021 | 163,538.00 |
| Jun 30, 2021 | 187,966.00 |
| Mar 31, 2021 | 106,898.00 |
| Dec 31, 2020 | 220,469.00 |
| Sep 30, 2020 | 260,972.00 |
| Jun 30, 2020 | 153,917.00 |
| Mar 31, 2020 | 178,403.00 |
| Dec 31, 2019 | 210,904.00 |
| Sep 30, 2019 | 143,620.00 |
| Jun 30, 2019 | 153,340.00 |